All‐cause mortality versus cancer‐specific mortality as outcome in cancer screening trials: A review and modeling study. (18th August 2019)

• Record Type: Journal Article
• Authors: Heijnsdijk, Eveline A. M.; Csanádi, Marcell; Gini, Andrea; ten Haaf, Kevin; Bendes, Rita; Anttila, Ahti; Senore, Carlo; de Koning, Harry J.
• Is Part Of: Cancer medicine. Volume 8:Number 13(2019:Oct.)
• Page Start: 6127
• Page End: 6138
• Publication Date: 2019-08-18
• Subjects: breast -- cancer screening -- colorectal -- evaluation -- lung -- mortality reduction -- trial; 616.994005
• DOI: 10.1002/cam4.2476
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Background: All‐cause mortality has been suggested as an end‐point in cancer screening trials in order to avoid biases in attributing the cause of death. The aim of this study was to investigate which sample size and follow‐up is needed to find a significant reduction in all‐cause mortality. Methods: A literature review was conducted to identify previous studies that modeled the effect of screening on all‐cause mortality. Microsimulation modeling was used to simulate breast cancer, lung cancer, and colorectal cancer screening trials. Model outputs were: cancer‐specific deaths, all‐cause deaths, and life‐years gained per year of follow‐up. Results: There were large differences between the evaluated cancers. For lung cancer, when 40 000 high‐risk people are randomized to each arm, a significant reduction in all‐cause mortality could be expected between 11 and 13 years of follow‐up. For breast cancer, a significant reduction could be found between 16 and 26 years of follow‐up for a sample size of over 300 000 women in each arm. For colorectal cancer, 600 000 persons in each arm were required to be followed for 15‐20 years. Our systematic literature review identified seven papers, which showed highly similar results to our estimates. Conclusion: Cancer screening trials are able to demonstrate a significant reduction in all‐cause mortality due to screening, but require very large sample sizes. Depending on the cancer, 40 000‐600 000 participants per arm are needed to demonstrate a significant reduction. The reduction in all‐cause mortality can only be detected between specific years of follow‐up, more limited than the timeframe to detect a reduction in cancer‐specific mortality. Abstract : Cancer screening trials are only able to demonstrate a statistically significant difference in all‐cause mortality when 40 000‐600 000 participants per arm are participating. In addition, this significant difference can only be observed between a limited period of follow‐up.